The nice people at “Transfusion
News” sent their update today. As always, all good stuff…
Iron Repletion Does Not Effect Donor Well-Being or Red Cell Quality
 | | September 28, 2022 | | Iron
deficiency develops in over one third of regular, repeat blood donors.
In order to exam the physiological consequences of iron deficiency in
blood donors, a randomized, double-blind, placebo-controlled trial
(Donor Iron Deficiency Study [DIDS]) screened 2,011 adult blood donors. [Read More] |
|
 | | In
this new Transfusion Science Webinar, Karina Yazdanbakhsh, PhD, will
discuss our current understanding of hemolytic transfusion reactions
(HTR) in patients with sickle cell disease, with a focus on potential
pathophysiologic mechanisms, recommended approaches to managing HTR, and
strategies to prevent the development of HTR. [Register Now] |
|
 | |
| Join
Transfusion News Associate Editors Daniela Hermelin and Monica Pagano
on Twitter Space this Friday September 30 at 11:00 AM ET for a
#Blooducation Baristas live event. Dr. Hermelin and Dr. Pagano will be
joined by Richard Godby, Tiffani Skinner-Jackson and Patrick McGann to
discuss Sickle Cell Disease Advocacy. [Set a reminder to join us] |
|
 | | September 21, 2022 | | Patients
with hematologic malignancies account for 43% of the 2 million platelet
doses transfused in the U.S. each year. Despite prophylactic platelet
transfusions, 43% of patients with hematologic malignancies still
experience WHO grade 2 bleeding or higher. Tranexamic acid (TXA) is
commonly used to prevent bleeding and mortality in a many patients
including orthopedic, cardiothoracic, organ transplant, trauma, and
obstetrical. [Read More] |
|
No comments:
Post a Comment